Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > The flaw with TLT
View:
Post by Systemtogo on Feb 01, 2022 11:06pm

The flaw with TLT

The major flaw in it being used as a cancer treatment is that cancer is a metabolic disease of damaged mitochondria. Cancer feeds off of glucose and glutamine. Therefore, TLT's technology, like chemotherapy, doesn't get to the root of the problem and may even make patients worse by deflecting proper treatment. Thats not to say it doesn't have other therapeutic potential.
Comment by Galaxym31 on Feb 01, 2022 11:18pm
Nice try but lame .
Comment by robertshaw on Feb 01, 2022 11:33pm
agree, another Blowjobjoe
Comment by CancerSlayer on Feb 02, 2022 12:11am
What a flawed argument...recommend you stick with a subject you're used to...CON mining.  
Comment by Yajne on Feb 02, 2022 12:14am
I've been wondering how long before the FUD peddlers arrive on TLT board. You must have been sleeping under a rock not to know TLT's progress 
Comment by menoalittle on Feb 02, 2022 1:07am
I nearly burst out laughing when I first read it...
Comment by Oilminerdeluxe on Feb 02, 2022 3:00am
Dear God in heaven.
Comment by fredgoodwinson on Feb 02, 2022 3:37am
Subtle as a brick - but interesting to see the re-appearance of naked bashing.
Comment by Infinity on Feb 02, 2022 4:47am
Hey System to go,  Don't hold hold back let your system to go.  You are so full of Sheettttttttt.
Comment by anabelsi on Feb 02, 2022 9:04am
Man you guys are not even trying anymore lol
Theralase Technologies Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250